poisar

Stocks · News reference

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47

Benzinga Newsdesk

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TEVA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGR

    The global brain health supplements market is projected to grow from USD 12.47 billion in 2025 to USD 35.41 billion by 2035, driven by increasing consumer awareness of cognitive wellness, demand for natural ingredients, and e-commerce expansion. North America leads with 43.1% market share, while memory enhancement remains the top application. Key growth factors include aging populations, younger consumers seeking cognitive support, and clinical validation of natural ingredients like Bacopa monnieri and Ginkgo Biloba.

    TEVARBGLY
  2. Na

    Teva to Host R&D Day on Wednesday, November 11 in New York City

    Teva Pharmaceutical Industries announced it will host an R&D Day on November 11, 2026, in New York to discuss its R&D pipeline and transformation strategy into an innovative biopharma company. The company also announced FDA approval of WELTRUZA™ (olanzapine), the first and only once-monthly subcutaneous injectable olanzapine for adults with schizophrenia.

    TEVA
  3. Na

    J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?

    Johnson & Johnson will report Q3 2026 results on October 13 with consensus estimates for $25.37 billion in sales and $2.66 EPS. The company's Innovative Medicine segment is expected to drive growth through key drugs like Darzalex and new launches, but faces headwinds from Stelara biosimilar competition and upcoming patent expirations. Despite valuation concerns, analysts recommend staying invested given J&J's diversified business model, consistent growth trajectory, and pipeline strength.

    JNJAMGNTEVA